The global market for Psychiatric API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Psychiatric API, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Psychiatric API by region & country, by Type, and by Application.

The Psychiatric API market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychiatric API.

Market Segmentation

Scope of Psychiatric API - Market Report

Report Metric	Details
Report Name	Psychiatric API - Market
CAGR	5%
Segment by Type:	Venlafaxine Duloxetine Olanzapine Paroxetine Others
Segment by Application	Major Depressive Disorder Generalized Anxiety Disorder Fibromyalgia Schizophrenia Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Eli Lilly, Salutas Pharma, Bora Pharmaceutical, Dr.Reddy's Laboratories, Germany Pharmaceutical, Hengrui Pharmaceuticals, Herui Pharmaceutical, Ren An Pharmaceutical, Yaopharma, Kanghong Pharmaceutical, Brilliant Pharmaceutical, Dongting Pharmaceutical, Sichuan Chuanda West China Pharmaceutical, Yangtze River Pharmaceutical, Huahai Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Psychiatric API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Psychiatric API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Psychiatric API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Psychiatric API - Market report?

Ans: The main players in the Psychiatric API - Market are Pfizer, Eli Lilly, Salutas Pharma, Bora Pharmaceutical, Dr.Reddy's Laboratories, Germany Pharmaceutical, Hengrui Pharmaceuticals, Herui Pharmaceutical, Ren An Pharmaceutical, Yaopharma, Kanghong Pharmaceutical, Brilliant Pharmaceutical, Dongting Pharmaceutical, Sichuan Chuanda West China Pharmaceutical, Yangtze River Pharmaceutical, Huahai Pharmaceutical

What are the Application segmentation covered in the Psychiatric API - Market report?

Ans: The Applications covered in the Psychiatric API - Market report are Major Depressive Disorder, Generalized Anxiety Disorder, Fibromyalgia, Schizophrenia, Others

What are the Type segmentation covered in the Psychiatric API - Market report?

Ans: The Types covered in the Psychiatric API - Market report are Venlafaxine, Duloxetine, Olanzapine, Paroxetine, Others

1 Market Overview

1.1 Psychiatric API Product Introduction

1.2 Global Psychiatric API Market Size Forecast

1.2.1 Global Psychiatric API Sales Value (2019-2030)

1.2.2 Global Psychiatric API Sales Volume (2019-2030)

1.2.3 Global Psychiatric API Sales Price (2019-2030)

1.3 Psychiatric API Market Trends & Drivers

1.3.1 Psychiatric API Industry Trends

1.3.2 Psychiatric API Market Drivers & Opportunity

1.3.3 Psychiatric API Market Challenges

1.3.4 Psychiatric API Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Psychiatric API Players Revenue Ranking (2023)

2.2 Global Psychiatric API Revenue by Company (2019-2024)

2.3 Global Psychiatric API Players Sales Volume Ranking (2023)

2.4 Global Psychiatric API Sales Volume by Company Players (2019-2024)

2.5 Global Psychiatric API Average Price by Company (2019-2024)

2.6 Key Manufacturers Psychiatric API Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Psychiatric API Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Psychiatric API

2.9 Psychiatric API Market Competitive Analysis

2.9.1 Psychiatric API Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Psychiatric API Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric API as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Venlafaxine

3.1.2 Duloxetine

3.1.3 Olanzapine

3.1.4 Paroxetine

3.1.5 Others

3.2 Global Psychiatric API Sales Value by Type

3.2.1 Global Psychiatric API Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Psychiatric API Sales Value, by Type (2019-2030)

3.2.3 Global Psychiatric API Sales Value, by Type (%) (2019-2030)

3.3 Global Psychiatric API Sales Volume by Type

3.3.1 Global Psychiatric API Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Psychiatric API Sales Volume, by Type (2019-2030)

3.3.3 Global Psychiatric API Sales Volume, by Type (%) (2019-2030)

3.4 Global Psychiatric API Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Major Depressive Disorder

4.1.2 Generalized Anxiety Disorder

4.1.3 Fibromyalgia

4.1.4 Schizophrenia

4.1.5 Others

4.2 Global Psychiatric API Sales Value by Application

4.2.1 Global Psychiatric API Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Psychiatric API Sales Value, by Application (2019-2030)

4.2.3 Global Psychiatric API Sales Value, by Application (%) (2019-2030)

4.3 Global Psychiatric API Sales Volume by Application

4.3.1 Global Psychiatric API Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Psychiatric API Sales Volume, by Application (2019-2030)

4.3.3 Global Psychiatric API Sales Volume, by Application (%) (2019-2030)

4.4 Global Psychiatric API Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Psychiatric API Sales Value by Region

5.1.1 Global Psychiatric API Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Psychiatric API Sales Value by Region (2019-2024)

5.1.3 Global Psychiatric API Sales Value by Region (2025-2030)

5.1.4 Global Psychiatric API Sales Value by Region (%), (2019-2030)

5.2 Global Psychiatric API Sales Volume by Region

5.2.1 Global Psychiatric API Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Psychiatric API Sales Volume by Region (2019-2024)

5.2.3 Global Psychiatric API Sales Volume by Region (2025-2030)

5.2.4 Global Psychiatric API Sales Volume by Region (%), (2019-2030)

5.3 Global Psychiatric API Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Psychiatric API Sales Value, 2019-2030

5.4.2 North America Psychiatric API Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Psychiatric API Sales Value, 2019-2030

5.5.2 Europe Psychiatric API Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Psychiatric API Sales Value, 2019-2030

5.6.2 Asia Pacific Psychiatric API Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Psychiatric API Sales Value, 2019-2030

5.7.2 South America Psychiatric API Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Psychiatric API Sales Value, 2019-2030

5.8.2 Middle East & Africa Psychiatric API Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Psychiatric API Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Psychiatric API Sales Value

6.2.1 Key Countries/Regions Psychiatric API Sales Value, 2019-2030

6.2.2 Key Countries/Regions Psychiatric API Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Psychiatric API Sales Value, 2019-2030

6.3.2 United States Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Psychiatric API Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Psychiatric API Sales Value, 2019-2030

6.4.2 Europe Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Psychiatric API Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Psychiatric API Sales Value, 2019-2030

6.5.2 China Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.5.3 China Psychiatric API Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Psychiatric API Sales Value, 2019-2030

6.6.2 Japan Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Psychiatric API Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Psychiatric API Sales Value, 2019-2030

6.7.2 South Korea Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Psychiatric API Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Psychiatric API Sales Value, 2019-2030

6.8.2 Southeast Asia Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Psychiatric API Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Psychiatric API Sales Value, 2019-2030

6.9.2 India Psychiatric API Sales Value by Type (%), 2023 VS 2030

6.9.3 India Psychiatric API Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer

7.1.1 Pfizer Company Information

7.1.2 Pfizer Introduction and Business Overview

7.1.3 Pfizer Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Pfizer Psychiatric API Product Offerings

7.1.5 Pfizer Recent Development

7.2 Eli Lilly

7.2.1 Eli Lilly Company Information

7.2.2 Eli Lilly Introduction and Business Overview

7.2.3 Eli Lilly Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Eli Lilly Psychiatric API Product Offerings

7.2.5 Eli Lilly Recent Development

7.3 Salutas Pharma

7.3.1 Salutas Pharma Company Information

7.3.2 Salutas Pharma Introduction and Business Overview

7.3.3 Salutas Pharma Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Salutas Pharma Psychiatric API Product Offerings

7.3.5 Salutas Pharma Recent Development

7.4 Bora Pharmaceutical

7.4.1 Bora Pharmaceutical Company Information

7.4.2 Bora Pharmaceutical Introduction and Business Overview

7.4.3 Bora Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Bora Pharmaceutical Psychiatric API Product Offerings

7.4.5 Bora Pharmaceutical Recent Development

7.5 Dr.Reddy's Laboratories

7.5.1 Dr.Reddy's Laboratories Company Information

7.5.2 Dr.Reddy's Laboratories Introduction and Business Overview

7.5.3 Dr.Reddy's Laboratories Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Dr.Reddy's Laboratories Psychiatric API Product Offerings

7.5.5 Dr.Reddy's Laboratories Recent Development

7.6 Germany Pharmaceutical

7.6.1 Germany Pharmaceutical Company Information

7.6.2 Germany Pharmaceutical Introduction and Business Overview

7.6.3 Germany Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Germany Pharmaceutical Psychiatric API Product Offerings

7.6.5 Germany Pharmaceutical Recent Development

7.7 Hengrui Pharmaceuticals

7.7.1 Hengrui Pharmaceuticals Company Information

7.7.2 Hengrui Pharmaceuticals Introduction and Business Overview

7.7.3 Hengrui Pharmaceuticals Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Hengrui Pharmaceuticals Psychiatric API Product Offerings

7.7.5 Hengrui Pharmaceuticals Recent Development

7.8 Herui Pharmaceutical

7.8.1 Herui Pharmaceutical Company Information

7.8.2 Herui Pharmaceutical Introduction and Business Overview

7.8.3 Herui Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Herui Pharmaceutical Psychiatric API Product Offerings

7.8.5 Herui Pharmaceutical Recent Development

7.9 Ren An Pharmaceutical

7.9.1 Ren An Pharmaceutical Company Information

7.9.2 Ren An Pharmaceutical Introduction and Business Overview

7.9.3 Ren An Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Ren An Pharmaceutical Psychiatric API Product Offerings

7.9.5 Ren An Pharmaceutical Recent Development

7.10 Yaopharma

7.10.1 Yaopharma Company Information

7.10.2 Yaopharma Introduction and Business Overview

7.10.3 Yaopharma Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Yaopharma Psychiatric API Product Offerings

7.10.5 Yaopharma Recent Development

7.11 Kanghong Pharmaceutical

7.11.1 Kanghong Pharmaceutical Company Information

7.11.2 Kanghong Pharmaceutical Introduction and Business Overview

7.11.3 Kanghong Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Kanghong Pharmaceutical Psychiatric API Product Offerings

7.11.5 Kanghong Pharmaceutical Recent Development

7.12 Brilliant Pharmaceutical

7.12.1 Brilliant Pharmaceutical Company Information

7.12.2 Brilliant Pharmaceutical Introduction and Business Overview

7.12.3 Brilliant Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.12.4 Brilliant Pharmaceutical Psychiatric API Product Offerings

7.12.5 Brilliant Pharmaceutical Recent Development

7.13 Dongting Pharmaceutical

7.13.1 Dongting Pharmaceutical Company Information

7.13.2 Dongting Pharmaceutical Introduction and Business Overview

7.13.3 Dongting Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.13.4 Dongting Pharmaceutical Psychiatric API Product Offerings

7.13.5 Dongting Pharmaceutical Recent Development

7.14 Sichuan Chuanda West China Pharmaceutical

7.14.1 Sichuan Chuanda West China Pharmaceutical Company Information

7.14.2 Sichuan Chuanda West China Pharmaceutical Introduction and Business Overview

7.14.3 Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.14.4 Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Offerings

7.14.5 Sichuan Chuanda West China Pharmaceutical Recent Development

7.15 Yangtze River Pharmaceutical

7.15.1 Yangtze River Pharmaceutical Company Information

7.15.2 Yangtze River Pharmaceutical Introduction and Business Overview

7.15.3 Yangtze River Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.15.4 Yangtze River Pharmaceutical Psychiatric API Product Offerings

7.15.5 Yangtze River Pharmaceutical Recent Development

7.16 Huahai Pharmaceutical

7.16.1 Huahai Pharmaceutical Company Information

7.16.2 Huahai Pharmaceutical Introduction and Business Overview

7.16.3 Huahai Pharmaceutical Psychiatric API Sales, Revenue and Gross Margin (2019-2024)

7.16.4 Huahai Pharmaceutical Psychiatric API Product Offerings

7.16.5 Huahai Pharmaceutical Recent Development

8 Industry Chain Analysis

8.1 Psychiatric API Industrial Chain

8.2 Psychiatric API Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Psychiatric API Sales Model

8.5.2 Sales Channel

8.5.3 Psychiatric API Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Eli Lilly

Dr. Reddy’s Laboratories

Hengrui Pharmaceuticals

YaoPharma

Kanghong Pharmaceutical

Brilliant Pharmaceutical

Dongting Pharmaceutical

Yangtze River Pharmaceutical

Huahai Pharmaceutical

Salutas Pharma

Bora Pharmaceutical

Germany Pharmaceutical

Herui Pharmaceutical

Ren An Pharmaceutical

Sichuan Chuanda West China Pharmaceutical

Pfizer Inc

List of Tables

Table 1. Psychiatric API Market Trends

Table 2. Psychiatric API Market Drivers & Opportunity

Table 3. Psychiatric API Market Challenges

Table 4. Psychiatric API Market Restraints

Table 5. Global Psychiatric API Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Psychiatric API Revenue Market Share by Company (2019-2024)

Table 7. Global Psychiatric API Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Psychiatric API Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Psychiatric API Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Psychiatric API Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Psychiatric API Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Psychiatric API

Table 13. Global Psychiatric API Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychiatric API as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Psychiatric API Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Psychiatric API Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Psychiatric API Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Psychiatric API Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Psychiatric API Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Psychiatric API Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Psychiatric API Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Psychiatric API Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Psychiatric API Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Psychiatric API Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Psychiatric API Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Psychiatric API Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Psychiatric API Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Psychiatric API Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Psychiatric API Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Psychiatric API Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Psychiatric API Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Psychiatric API Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Psychiatric API Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Psychiatric API Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Psychiatric API Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Psychiatric API Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Psychiatric API Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Psychiatric API Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Psychiatric API Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Psychiatric API Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Psychiatric API Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Psychiatric API Sales Value by Region (2019-2024) & (%)

Table 44. Global Psychiatric API Sales Value by Region (2025-2030) & (%)

Table 45. Global Psychiatric API Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Psychiatric API Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Psychiatric API Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Psychiatric API Sales Volume by Region (2019-2024) & (%)

Table 49. Global Psychiatric API Sales Volume by Region (2025-2030) & (%)

Table 50. Global Psychiatric API Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Psychiatric API Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Psychiatric API Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Psychiatric API Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Psychiatric API Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Psychiatric API Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Psychiatric API Sales Volume, (2025-2030) & (K Units)

Table 57. Pfizer Company Information

Table 58. Pfizer Introduction and Business Overview

Table 59. Pfizer Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Pfizer Psychiatric API Product Offerings

Table 61. Pfizer Recent Development

Table 62. Eli Lilly Company Information

Table 63. Eli Lilly Introduction and Business Overview

Table 64. Eli Lilly Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Eli Lilly Psychiatric API Product Offerings

Table 66. Eli Lilly Recent Development

Table 67. Salutas Pharma Company Information

Table 68. Salutas Pharma Introduction and Business Overview

Table 69. Salutas Pharma Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Salutas Pharma Psychiatric API Product Offerings

Table 71. Salutas Pharma Recent Development

Table 72. Bora Pharmaceutical Company Information

Table 73. Bora Pharmaceutical Introduction and Business Overview

Table 74. Bora Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Bora Pharmaceutical Psychiatric API Product Offerings

Table 76. Bora Pharmaceutical Recent Development

Table 77. Dr.Reddy's Laboratories Company Information

Table 78. Dr.Reddy's Laboratories Introduction and Business Overview

Table 79. Dr.Reddy's Laboratories Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Dr.Reddy's Laboratories Psychiatric API Product Offerings

Table 81. Dr.Reddy's Laboratories Recent Development

Table 82. Germany Pharmaceutical Company Information

Table 83. Germany Pharmaceutical Introduction and Business Overview

Table 84. Germany Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Germany Pharmaceutical Psychiatric API Product Offerings

Table 86. Germany Pharmaceutical Recent Development

Table 87. Hengrui Pharmaceuticals Company Information

Table 88. Hengrui Pharmaceuticals Introduction and Business Overview

Table 89. Hengrui Pharmaceuticals Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Hengrui Pharmaceuticals Psychiatric API Product Offerings

Table 91. Hengrui Pharmaceuticals Recent Development

Table 92. Herui Pharmaceutical Company Information

Table 93. Herui Pharmaceutical Introduction and Business Overview

Table 94. Herui Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Herui Pharmaceutical Psychiatric API Product Offerings

Table 96. Herui Pharmaceutical Recent Development

Table 97. Ren An Pharmaceutical Company Information

Table 98. Ren An Pharmaceutical Introduction and Business Overview

Table 99. Ren An Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Ren An Pharmaceutical Psychiatric API Product Offerings

Table 101. Ren An Pharmaceutical Recent Development

Table 102. Yaopharma Company Information

Table 103. Yaopharma Introduction and Business Overview

Table 104. Yaopharma Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Yaopharma Psychiatric API Product Offerings

Table 106. Yaopharma Recent Development

Table 107. Kanghong Pharmaceutical Company Information

Table 108. Kanghong Pharmaceutical Introduction and Business Overview

Table 109. Kanghong Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Kanghong Pharmaceutical Psychiatric API Product Offerings

Table 111. Kanghong Pharmaceutical Recent Development

Table 112. Brilliant Pharmaceutical Company Information

Table 113. Brilliant Pharmaceutical Introduction and Business Overview

Table 114. Brilliant Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 115. Brilliant Pharmaceutical Psychiatric API Product Offerings

Table 116. Brilliant Pharmaceutical Recent Development

Table 117. Dongting Pharmaceutical Company Information

Table 118. Dongting Pharmaceutical Introduction and Business Overview

Table 119. Dongting Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 120. Dongting Pharmaceutical Psychiatric API Product Offerings

Table 121. Dongting Pharmaceutical Recent Development

Table 122. Sichuan Chuanda West China Pharmaceutical Company Information

Table 123. Sichuan Chuanda West China Pharmaceutical Introduction and Business Overview

Table 124. Sichuan Chuanda West China Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 125. Sichuan Chuanda West China Pharmaceutical Psychiatric API Product Offerings

Table 126. Sichuan Chuanda West China Pharmaceutical Recent Development

Table 127. Yangtze River Pharmaceutical Company Information

Table 128. Yangtze River Pharmaceutical Introduction and Business Overview

Table 129. Yangtze River Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 130. Yangtze River Pharmaceutical Psychiatric API Product Offerings

Table 131. Yangtze River Pharmaceutical Recent Development

Table 132. Huahai Pharmaceutical Company Information

Table 133. Huahai Pharmaceutical Introduction and Business Overview

Table 134. Huahai Pharmaceutical Psychiatric API Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 135. Huahai Pharmaceutical Psychiatric API Product Offerings

Table 136. Huahai Pharmaceutical Recent Development

Table 137. Key Raw Materials Lists

Table 138. Raw Materials Key Suppliers Lists

Table 139. Psychiatric API Downstream Customers

Table 140. Psychiatric API Distributors List

Table 141. Research Programs/Design for This Report

Table 142. Key Data Information from Secondary Sources

Table 143. Key Data Information from Primary Sources

List of Figures

Figure 1. Psychiatric API Product Picture

Figure 2. Global Psychiatric API Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Psychiatric API Sales Volume (2019-2030) & (K Units)

Figure 5. Global Psychiatric API Sales Price (2019-2030) & (US$/Unit)

Figure 6. Psychiatric API Report Years Considered

Figure 7. Global Psychiatric API Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Psychiatric API Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Psychiatric API Revenue in 2023

Figure 10. Psychiatric API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. Venlafaxine Picture

Figure 12. Duloxetine Picture

Figure 13. Olanzapine Picture

Figure 14. Paroxetine Picture

Figure 15. Others Picture

Figure 16. Global Psychiatric API Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Psychiatric API Sales Value Market Share by Type, 2023 & 2030

Figure 18. Global Psychiatric API Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 19. Global Psychiatric API Sales Volume Market Share by Type, 2023 & 2030

Figure 20. Global Psychiatric API Price by Type (2019-2030) & (US$/Unit)

Figure 21. Product Picture of Major Depressive Disorder

Figure 22. Product Picture of Generalized Anxiety Disorder

Figure 23. Product Picture of Fibromyalgia

Figure 24. Product Picture of Schizophrenia

Figure 25. Product Picture of Others

Figure 26. Global Psychiatric API Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 27. Global Psychiatric API Sales Value Market Share by Application, 2023 & 2030

Figure 28. Global Psychiatric API Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 29. Global Psychiatric API Sales Volume Market Share by Application, 2023 & 2030

Figure 30. Global Psychiatric API Price by Application (2019-2030) & (US$/Unit)

Figure 31. North America Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 32. North America Psychiatric API Sales Value by Country (%), 2023 VS 2030

Figure 33. Europe Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 34. Europe Psychiatric API Sales Value by Country (%), 2023 VS 2030

Figure 35. Asia Pacific Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Psychiatric API Sales Value by Country (%), 2023 VS 2030

Figure 37. South America Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 38. South America Psychiatric API Sales Value by Country (%), 2023 VS 2030

Figure 39. Middle East & Africa Psychiatric API Sales Value (2019-2030) & (US$ Million)

Figure 40. Middle East & Africa Psychiatric API Sales Value by Country (%), 2023 VS 2030

Figure 41. Key Countries/Regions Psychiatric API Sales Value (%), (2019-2030)

Figure 42. Key Countries/Regions Psychiatric API Sales Volume (%), (2019-2030)

Figure 43. United States Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 44. United States Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 45. United States Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 46. Europe Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 47. Europe Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 48. Europe Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 49. China Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 50. China Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 51. China Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 52. Japan Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 53. Japan Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 54. Japan Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 55. South Korea Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 56. South Korea Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 57. South Korea Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 58. Southeast Asia Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 59. Southeast Asia Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 60. Southeast Asia Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 61. India Psychiatric API Sales Value, (2019-2030) & (US$ Million)

Figure 62. India Psychiatric API Sales Value by Type (%), 2023 VS 2030

Figure 63. India Psychiatric API Sales Value by Application (%), 2023 VS 2030

Figure 64. Psychiatric API Industrial Chain

Figure 65. Psychiatric API Manufacturing Cost Structure

Figure 66. Channels of Distribution (Direct Sales, and Distribution)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions